Levodopa
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1970
- First approval year
- 1970
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Levodopa
- Molecular weight
- 197.19
- Structure (SMILES)
- N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O
- bendopa
- Bendopa
- brocadopa
- Brocadopa
- dopar
- Dopar
- inbrija
- Inbrija
- larodopa
- Larodopa
- Levodopa component of /carbidopa/entacapone orion
- levodopa component of carbidopa entacapone orion
- levodopa component of corbilta
- Levodopa component of corbilta
- levodopa component of crexont
- Levodopa component of crexont
- levodopa component of dhivy
- Levodopa component of dhivy
- levodopa component of dopasnap
- Levodopa component of dopasnap
- levodopa component of duopa
- Levodopa component of duopa
- levodopa component of ipx 203
- Levodopa component of ipx-203
- levodopa component of ipx203
And 7 more, listed on the interactive page.
- 200 mg levodopa 50 mg benserazide
- carbidopa and levodopa tablets
- carbilev component levodopa
- CARBILEV COMPONENT LEVODOPA
- corbilta component levodopa
- CORBILTA COMPONENT LEVODOPA
- crexont component levodopa
- CREXONT COMPONENT LEVODOPA
- cvt 301
- Cvt-301
- CVT-301
- CVT-301 (Dose Level 1)
- CVT-301 (Dose Level 2)
- CVT-301 (levodopa inhalation powder)
- dhivy component levodopa
- DHIVY COMPONENT LEVODOPA
- dopasnap component levodopa
- DOPASNAP COMPONENT LEVODOPA
- duopa component levodopa
- DUOPA COMPONENT LEVODOPA
- INBRIJA®
- Intravenous Levodopa
- ipx 203 component levodopa
- IPX-203 COMPONENT LEVODOPA
- ipx203 component levodopa
And 64 more, listed on the interactive page.
- ATC classification codes
- N04BA01
Sources for recorded values
- CAS registry numbers
- 59-92-7
- ChEMBL ID
- CHEMBL1009
- InChIKey
- WTDRDQBEARUVNC-LURJTMIESA-N
- RxNorm IDs (RxCUI)
- 6375
- FDA ingredient codes (UNII)
- 46627O600J
- 6047
- 6971033
- Applicant
- ORGANON
- Approval date
- 2 May 1975
- Application number
- NDA017555
- Status
- Authorised
- Status date
- 19 Sept 2019
- Authorisation date
- 19 Sept 2019
- Approved indications
- Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.
- Product number
- EMEA/H/C/004786
- Authorisation holder
- Merz Therapeutics GmbH
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Parkinson Disease
European medicines record
- Patents
- 6
- Designations
- 0
- Earliest recorded loss of exclusivity
- 21 Oct 2033
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- levodopa
- Type
- Metabolite
- Drug name stem
- -dopa
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- topical
- Action
- Agonist
- Action type
- Agonist
- Target
- GPR143
- Gene symbol
- GPR143
- Protein identifier
- P51810
- Mechanism
- Dopamine D3 receptor agonist
- Action type
- Agonist
- Target
- D(3) dopamine receptor
- Protein identifier
- P35462
Open Targets mechanisms
- Mechanism
- Dopamine D3 receptor agonist
- Action type
- Agonist
- Target
- D(3) dopamine receptor
- Action type
- Agonist
- Gene symbol
- DRD2
- Protein identifier
- P14416
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Agonist
- Gene symbol
- DRD1
- Protein identifier
- P21728
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Stroke
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000712
- Subject identifier
- D020521
- Condition
- Stress Disorders, Post-Traumatic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001358
- Subject identifier
- D013313
- Condition
- Macular Degeneration
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001365
- Subject identifier
- D008268
- Condition
- Cocaine-Related Disorders
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002610
- Subject identifier
- D019970
- Condition
- Child Development Disorders, Pervasive
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003756
- Subject identifier
- D002659
- Condition
- Tobacco Use Disorder
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003768
- Subject identifier
- D014029
- Condition
- Diabetic Retinopathy
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0003770
- Subject identifier
- D003930
- Condition
- Pain
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003843
- Subject identifier
- D010146
- Condition
- Restless Legs Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004270
- Subject identifier
- D012148
- Condition
- Tourette Syndrome
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004895
- Subject identifier
- D005879
- Condition
- Hypotension, Orthostatic
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005252
- Subject identifier
- D007024
- Condition
- Spinal Cord Injuries
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001919
- Subject identifier
- D013119
- Condition
- Aphasia
- Highest recorded phase
- 2
- Condition identifier
- HP:0002381
- Subject identifier
- D001037
- Condition
- Back Pain
- Highest recorded phase
- 2
- Condition identifier
- HP:0003418
- Subject identifier
- D001416
- Condition
- Chronic Pain
- Highest recorded phase
- 2
- Condition identifier
- HP:0012532
- Subject identifier
- D059350
- Condition
- Amblyopia
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0001020
- Subject identifier
- D000550
- Condition
- Cocaine-Related Disorders
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004456
- Subject identifier
- D019970
- Condition
- Amyotrophic Lateral Sclerosis
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004976
- Subject identifier
- D000690
- Condition
- Asthma
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001249
- Condition
- Schizophrenia
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005090
- Subject identifier
- D012559
- Condition
- Parkinson Disease
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0005180
- Subject identifier
- D010300
- Condition
- Angelman Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007113
- Subject identifier
- D017204
- Condition
- Albinism, Oculocutaneous
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0018910
- Subject identifier
- D016115
- Condition
- Retinitis Pigmentosa
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0019200
- Subject identifier
- D012174
- Condition
- Albinism
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0043209
- Subject identifier
- D000417
And 2 more, listed on the interactive page.
- Condition identifier
- EFO_0000546
- Condition identifier
- EFO_0000712
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000721
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001358
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001365
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002610
- Condition identifier
- EFO_0003756
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003768
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003770
- Condition identifier
- EFO_0004270
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004895
- Highest recorded phase
- 1
- Condition identifier
- EFO_0010445
- Highest recorded phase
- 2
- Condition identifier
- EFO_0022861
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001050
- Condition identifier
- EFO_1001492
- Highest recorded phase
- 2
- Condition identifier
- HP_0001257
- Highest recorded phase
- 1
- Condition identifier
- HP_0001288
- Condition identifier
- HP_0001297
- Highest recorded phase
- 3
- Condition identifier
- HP_0001337
- Condition identifier
- HP_0002063
- Condition identifier
- HP_0002067
- Condition identifier
- HP_0002381
- Condition identifier
- HP_0002381
- Highest recorded phase
- 2
- Condition identifier
- HP_0003418
- Highest recorded phase
- 2
- Condition identifier
- HP_0012531
- Highest recorded phase
- 3
And 35 more, listed on the interactive page.
- Event
- abnormal dreams
- Reports
- 132
- Reporting signal score
- 200.404
- Event
- aggression
- Reports
- 214
- Reporting signal score
- 212.82
- Event
- agitation
- Reports
- 247
- Reporting signal score
- 179.925
- Event
- akinesia
- Reports
- 216
- Reporting signal score
- 808.15
- Event
- anxiety
- Reports
- 345
- Reporting signal score
- 135.199
- Event
- balance disorder
- Reports
- 262
- Reporting signal score
- 255.164
- Event
- bezoar
- Reports
- 62
- Reporting signal score
- 196.703
- Event
- bradykinesia
- Reports
- 230
- Reporting signal score
- 719.693
- Event
- c-reactive protein increased
- Reports
- 164
- Reporting signal score
- 140.673
- Event
- cognitive disorder
- Reports
- 291
- Reporting signal score
- 411.21
- Event
- compulsive shopping
- Reports
- 48
- Reporting signal score
- 152.442
- Event
- confusional state
- Reports
- 580
- Reporting signal score
- 519.864
- Event
- decubitus ulcer
- Reports
- 81
- Reporting signal score
- 149.272
- Event
- delirium
- Reports
- 195
- Reporting signal score
- 193.995
- Event
- delusion
- Reports
- 145
- Reporting signal score
- 237.891
- Event
- dementia
- Reports
- 172
- Reporting signal score
- 285.217
- Event
- device connection issue
- Reports
- 111
- Reporting signal score
- 426.295
- Event
- disorientation
- Reports
- 176
- Reporting signal score
- 167.191
- Event
- dopamine dysregulation syndrome
- Reports
- 157
- Reporting signal score
- 744.83
- Event
- dyskinesia
- Reports
- 1,152
- Reporting signal score
- 3,371.6
- Event
- dysphagia
- Reports
- 349
- Reporting signal score
- 292.632
- Event
- dystonia
- Reports
- 211
- Reporting signal score
- 388.362
- Event
- excessive granulation tissue
- Reports
- 47
- Reporting signal score
- 147.474
- Event
- fall
- Reports
- 1,504
- Reporting signal score
- 1,744.54
- Event
- femoral neck fracture
- Reports
- 88
- Reporting signal score
- 168.51
And 46 more, listed on the interactive page.
- NCT00004733
- NCT00006077
- NCT00006337
- NCT00009048
- NCT00013624
- NCT00040209
- NCT00076674
- NCT00086294
- NCT00089622
- NCT00099268
- NCT00108667
- NCT00125567
- NCT00134966
- NCT00141518
- NCT00143026
- NCT00153972
- NCT00174239
- NCT00219284
- NCT00253084
- NCT00272688
- NCT00279825
- NCT00335153
- NCT00357994
- NCT00360568
- NCT00391898
And 127 more, listed on the interactive page.
- Dose
- 25 mg/100 mg
- How often
- Three to four times daily
- Adjust according to response
- Individualized therapy
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 4
- Polar surface area
- 103.78
- Calculated partition coefficient (ALogP)
- 0.05
- Calculated partition coefficient (XLogP)
- -2.7
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 14
- Molecular formula
- C9H11NO4
- Monoisotopic mass
- 197.06880783
- Natural product
- Yes
- 0074-3012
- 0093-9701
- 0093-9702
- 0093-9703
- 0259-6142
- 0378-0088
- 0378-0094
- 0615-8460
- 0615-8461
- 0615-8516
- 0615-8536
- 0615-8555
- 0781-5613
- 0781-5625
- 0781-5637
- 0781-5641
- 0781-5654
- 0781-5669
- 0904-7501
- 0904-7549
- 10144-342
- 16571-157
- 16571-158
- 16571-159
- 16571-689
And 126 more, listed on the interactive page.
- Recorded assays
- 2,829
- Active assays
- 122
- Confirmatory
- Other
- Screening
- Summary
- Antiparkinson Agents
- Dopamine Agents
These details could not be displayed.
Related records
Trials (261)
- 1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)
- A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease
- A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Orthopedic Surgery
- A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease
- A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects
- A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease
- A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease
- A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients for Postoperative Pain Treatment in Orthopedic Surgery
- A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells
- A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis
- A Pilot Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops® Relative to INBRIJA®
- A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients
- A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects
- A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)
- A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)
- A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)
- A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004
- A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)
- A Study of K-645 in the Treatment of Multiple Migraine Attacks
- A Study of L-DOPA for Depression and Slowing in Older Adults
Approved for (1)
In development for (22)
- Age-related macular degeneration Phase 2
- Albinism Phase 2
- Amblyopia Phase 3
- Amyotrophic lateral sclerosis Phase 1
- Angelman syndrome Phase 2
- Aphasia Phase 2
- Asthma Phase 1
- Autism spectrum disorder Phase 2
- Brain injury Early phase 1
- Cocaine abuse Phase 2
- Cocaine dependence Phase 2
- Diabetic retinopathy Early phase 1
- Nicotine dependence Phase 1
- Oculocutaneous albinism Phase 2
- Orthostatic hypotension Phase 1
- Post-traumatic stress disorder Phase 2
- Restless legs syndrome Phase 3
- Retinitis pigmentosa Phase 2
- Schizophrenia Phase 2
- Spinal cord injury Phase 2
Other linked conditions (3)
Targets (1)
- DRD3 Dopamine D3 receptor agonist